To determine whether the increases in iTNFα+ CD14+ cells observed in the RA patients were due to adalimumab treatment or a consequence of the remission state, we analyzed RA patients in methotrexate-induced remission. The gene discussed is CD14; the disease is rheumatoid arthritis.